Calliditas Therapeutics AB - American Depositary Shares (CALT)
40.00
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 10th, 10:29 PM EDT
Detailed Quote
Previous Close
40.00
Open
-
Bid
20.29
Ask
60.85
Day's Range
N/A - N/A
52 Week Range
16.00 - 42.10
Volume
0
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
-
Chart
About Calliditas Therapeutics AB - American Depositary Shares (CALT)
Calliditas Therapeutics is a biopharmaceutical company focused on developing innovative treatments for rare and severe diseases. Their primary focus is on renal disorders, particularly a condition known as IgA nephropathy, which can lead to kidney damage and failure. By leveraging advanced scientific research and clinical development, Calliditas aims to provide effective therapies that address unmet medical needs, enhancing the quality of life for patients suffering from complex health issues. The company is committed to advancing its pipeline of treatments through rigorous clinical trials and collaborations within the healthcare community. Read More
CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.
Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi Kasei's global presence in immunology and renal disease markets, aligning with its strategic growth and expansion in the U.S. and Europe.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders.
CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a preliminary injuction in a patent infringement lawsuit against NeoGenomics' RaDar test.
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at
